Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Milrinone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The name of your medicine is Primacor 1mg/ml Solution for Injection (called Primacor in this leaflet). Primacor contains a medicine called milrinone. This belongs to a group of medicines called phosphodiesterase inhibitors. It works by making your heart muscle contract more strongly and your blood vessels become wider. This means blood can flow more easily making your heart pump blood more successfully. Primacor can be used for:
Do not use Primacor if: × You are allergic (hypersensitive) to milrinone or any of the other ingredients of Primacor (listed in section 6) Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue. × You have lost body fluids and are severely dehydrated. Do not use this medicine if any of the above apply to you. If you are not sure, talk to your doctor, nurse or pharmacist before using Primacor.
The following provides a guide to maintenance infusion delivery rate based upon a solution containing milrinone 200 μg/ml prepared by adding 40 ml diluent per 10 ml ampoule (400 ml diluent per 100 ml Primacor Injection). 0.45% saline, 0.9% saline or 5% glucose may be used as diluents. Primacor Injection Dose (μg/kg/min) 0.375 0.400 0.500 0.600 0.700 0.750
Infusion Delivery Rate (ml/kg/hr) 0.11 0.12 0.15 0.18 0.21 0.22
710686
Is this leaflet hard to see or read? Phone 0800 035 2525 for help
Code AC / Item : 710686 Description AC : Notice Primacor inj. 10 ml Grande Bretagne Destination : Date / Version : 18/09/2023 V1 210×148 mm Dimension : Double Pliée Type :
Polices / Fonts : Ocean Sans Pro Texte corps mini / Text size mini : 9 pt
Accord Spécification
Accord CQL
Code actuel / Current code : 705239 Couleur (s) / Color(s) : 1 Noir Plan N° : N 100
Modification(s) apportée(s) à cette version / Modification(s) brought to this version :
Please tell your doctor if:
e Primacor 3. How to use Primacor 4. Possible side effects 5. How to store Primacor 6. Contents of the pack and other information
to you
Injection Creatinine Clearance Primacor Dose (ml/min/1.73m2) (μg/kg/min) 5 0.20 10 0.23 20 0.28 30 0.33 40 0.38 50 0.43
Maintenance Infusion Delivery Rate (ml/kg/hr) 0.06 0.07 0.08 0.10 0.11 0.13
The infusion rate should be adjusted according to haemodynamic response. Elderly Experience so far suggests that no special dosage recommendations 2 are necessary.
710686
Solutions of different concentrations may be used according to patient fluid requirements. The duration of therapy should depend upon the patient's response. In congestive cardiac failure, patients have been maintained on the infusion for up to 5 days, although the usual period is 48 – 72 hours. In acute states following cardiac surgery, it is unlikely that treatment need be maintained for more than 12 hours. Renal impairment Dosage adjustment required. Data obtained from patients with severe renal impairment but without heart failure have demonstrated that the presence of renal impairment significantly increases the terminal elimination half-life of milrinone. For patients with clinical evidence of renal impairment, the loading dose is not affected, but the following maintenance infusion rates are recommended using the infusion solution described above.
Code AC / Item : 710686 Description AC : Notice Primacor inj. 10 ml Grande Bretagne Destination : Date / Version : 18/09/2023 V1 210×148 mm Dimension : Double Pliée Type :
Polices / Fonts : Ocean Sans Pro Texte corps mini / Text size mini : 9 pt
Accord Spécification
Accord CQL
Code actuel / Current code : 705239 Couleur (s) / Color(s) : 1 Noir Plan N° : N 100
Modification(s) apportée(s) à cette version / Modification(s) brought to this version :
Tell a doctor or nurse if any of the following side effects gets serious or lasts longer than a few days: Uncommon (affects less than 1 in 100 people)
Like all medicines, Primacor can cause side effects, although not everybody gets them. Stop using Primacor and tell you doctor straight away if:
710686
Paediatric population Renal impairment: Due to lack of data the use of milrinone is not recommended in In published studies selected doses for infants and children were:
Code AC / Item : 710686 Description AC : Notice Primacor inj. 10 ml Grande Bretagne Destination : Date / Version : 18/09/2023 V1 210×148 mm Dimension : Double Pliée Type :
Polices / Fonts : Ocean Sans Pro Texte corps mini / Text size mini : 9 pt
Accord Spécification
Accord CQL
Code actuel / Current code : 705239 Couleur (s) / Color(s) : 1 Noir Plan N° : N 100
Modification(s) apportée(s) à cette version / Modification(s) brought to this version :
Primacor This medicine will be kept by your doctor or pharmacist in a safe place where children cannot see or reach it. Do not use Primacor after the expiry date, which is stated on the ampoule and the carton. The expiry date refers to the last day of the month. Primacor should be stored below 25°C. Do not freeze. Do not throw away any medicines via wastewater or household waste. Your doctor or nurse will throw away medicines you no longer use. These measures will help protect the environment.
What Primacor contains
Special precautions for disposal Infusion solutions diluted as recommended with 0.45% saline, 0.9% saline or 5% glucose should be freshly prepared before use. Parenteral drug products should be examined visually and should not be used if particulate matter or discolouration are present.
710686
Incompatibilities Furosemide or bumetanide should not be administered in intravenous lines containing Primacor Injection since precipitation occurs on admixture. Sodium Bicarbonate Intravenous infusion should not be used for dilution. Other drugs should not be mixed with Primacor Injection until further compatibility data are available. Shelf life 36 months when unopened. A diluted solution of Primacor Injection should be used within 24 hours. Special precautions for storage Store below 25°C. Do not freeze.
4
Primacor 1mg/ml Solution for Injection comes as injection containing 1mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Primacor 1mg/ml Solution for Injection is milrinone.
Medicines with the same active substance, strength and form include: Milrinone 1 mg/ml Solution for Injection and Infusion., Milrinone 1mg/ml Solution for injection/infusion. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Primacor 1mg/ml Solution for Injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Primacor Injection is indicated for the short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy, and for the treatment of patients with acute heart failure, including low output states following cardiac surgery.
In paediatric population, Primacor is indicated for the short-term treatment (up to 35 hours) of severe congestive heart failure unresponsive to conventional maintenance therapy (glycosides, diuretics, vasodilators and/or angiotensin converting enzyme (ACE) inhibitors), and for the short-term treatment (up to 35 hours) of paediatric patients with acute heart failure, including low output states following cardiac surgery.
For intravenous administration.
Adults
Primacor Injection should be given as a loading dose of 50 µg/kg administered over a period of 10 minutes usually followed by a continuous infusion at a dosage titrated between 0.375 µg/kg/min and 0.75 µg/kg/min according to haemodynamic and clinical response, but should not exceed 1.13 mg/kg/day total dose.
The following provides a guide to maintenance infusion delivery rate based upon a solution containing milrinone 200 µg/ml prepared by adding 40 ml diluent per 10 ml ampoule (400 ml diluent per 100 ml Primacor Injection). 0.45% saline, 0.9% saline or 5% glucose may be used as diluents.
Primacor Injection Dose
(µg/kg/min)
Infusion Delivery Rate (ml/kg/hr)
0.375
0.400
0.500
0.600
0.700
0.750
0.11
0.12
0.15
0.18
0.21
0.22
Solutions of different concentrations may be used according to patient fluid requirements. The duration of therapy should depend upon the patient's response. In congestive cardiac failure, patients have been maintained on the infusion for up to 5 days, although the usual period is 48 – 72 hours. In acute states following cardiac surgery, it is unlikely that treatment need be maintained for more than 12 hours.
Renal impairment
Dosage adjustment required. Data obtained from patients with severe renal impairment but without heart failure have demonstrated that the presence of renal impairment significantly increases the terminal elimination half-life of milrinone. For patients with clinical evidence of renal impairment, the loading dose is not affected, but the following maintenance infusion rates are recommended using the infusion solution described above.
Creatinine Clearance
(ml/min/1.73m2)
Primacor Injection Dose
(µg/kg/min)
Maintenance Infusion Delivery Rate (ml/kg/hr)
5
10
20
30
40
50
0.20
0.23
0.28
0.33
0.38
0.43
0.06
0.07
0.08
0.10
0.11
0.13
The infusion rate should be adjusted according to haemodynamic response.
Elderly
Experience so far suggests that no special dosage recommendations are necessary.
Paediatric population
In published studies selected doses for infants and children were:
• Intravenous loading dose: 50 – 75 µg/kg administered over 30 – 60 minutes.
• Intravenous continuous infusion: To be initiated on the basis of hemodynamic response and the possible onset of undesirable effects between 0.25 – 0.75 µg/kg/min for a period up to 35 hours.
In clinical studies on low cardiac output syndrome in infants and children under 6 years of age after corrective surgery for congenital heart disease 75 µg/kg loading dose over 60 minutes followed by a 0.75 µg/kg/min infusion for 35 hours significantly reduced the risk of development of low cardiac output syndrome.
Results of pharmacokinetic studies (see section 5.2) have to be taken into consideration.
Renal impairment:
Due to lack of data the use of milrinone is not recommended in paediatric population with renal impairment (see section 4.4).
Patent ductus arteriosus:
If the use of milrinone is desirable in preterm or term infants at risk of/with patent ductus arteriosus, the therapeutic need must be weighed against potential risks (see sections 4.4, 4.8, 5.2, and 5.3).
• Hypersensitivity to milrinone or any of the excipients listed in section 6.1.
• Severe hypovolaemia.
The use of inotropic agents such as milrinone during the acute phase of a myocardial infarction may lead to an undesirable increase in myocardial oxygen consumption (MVO2). Primacor Injection is not recommended immediately following acute myocardial infarction until safety and efficacy have been established in this situation.
Careful monitoring should be maintained during Primacor Injection therapy including blood pressure, heart rate, clinical state, electro-cardiogram, fluid balance, electrolytes and renal function (i.e. serum creatinine).
In patients with severe obstructive aortic or pulmonary valvular disease, or hypertrophic subaortic stenosis, Primacor Injection should not be used in place of surgical relief of the obstruction. In these conditions it is possible that a drug with inotropic / vasodilator properties might aggravate outflow obstruction.
Supraventricular and ventricular arrhythmias have been observed in the high risk population treated with milrinone. In some patients, an increase in ventricular ectopy including non-sustained ventricular tachycardia has been observed which did not affect patient safety or outcome.
The potential for arrhythmia, present in heart failure itself, may be increased by many drugs or a combination of drugs. Patients receiving Primacor Injection should be closely monitored during infusion and the infusion should be stopped if arrhythmias develop.
As milrinone produces a slight enhancement in A-V node conduction, there is a possibility of an increased ventricular response rate in patients with uncontrolled atrial flutter / fibrillation. Consideration should therefore be given to digitalisation or treatment with other agents to prolong A-V node conduction time prior to starting Primacor Injection therapy, and to discontinuing the therapy if arrhythmias occur.
Milrinone may induce hypotension as a consequence of its vasodilatory activity; therefore caution should be exercised when Primacor Injection is administered to patients who are hypotensive prior to treatment. The rate of infusion should be slowed or stopped in patients showing excessive decreases in blood pressure.
If prior vigorous diuretic therapy is suspected of having caused significant decreases in cardiac filling pressure Primacor Injection should be cautiously administered while monitoring blood pressure, heart rate and clinical symptomatology.
Improvement in cardiac output with resultant diuresis may necessitate a reduction in the dose of diuretic. Potassium loss due to excessive diuresis may necessitate a reduction in the dose of diuretic. Potassium loss due to excessive diuresis may predispose digitalised patients to arrhythmias. Therefore, hypokalaemia should be corrected by potassium supplementation in advance of, or during, the use of Primacor Injection.
Decrease in haemoglobin, including anaemia, often takes place in the setting of cardiac failure. Due to the risk of thrombocytopenia or anaemia, careful monitoring of the corresponding laboratory parameters is required in patients with decreased platelet count or decreased haemoglobin
There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.
Cases of infusion site reaction have been reported with Primacor Injection (see section 4.8). Consequently, careful monitoring of the infusion site should be maintained so as to avoid possible extravasation.
Use in the elderly:
There are no special recommendations for elderly patients. No age-related effects on the incidence of adverse reactions have been observed. Controlled pharmacokinetic studies have not shown changes in the pharmacokinetic profile of milrinone in the elderly.
In patients with severe renal impairment dosage adjustment is required (see section 4.2).
Paediatric population
The following should be considered in addition to the warnings and precautions described for adults:
In neonates, following open heart surgery during Primacor therapy, monitoring should include heart rate and rhythm, systemic arterial blood pressure via umbilical artery catheter or peripheral catheter, central venous pressure, cardiac index, cardiac output, systemic vascular resistance, pulmonary artery pressure, and atrial pressure. Laboratory values that should be followed are platelet count, serum potassium, liver function, and renal function. Frequency of assessment is determined by baseline values, and it is necessary to evaluate the neonate's response to changes in therapy.
Literature revealed that in paediatric patients with impaired renal function, there were marked impairment of milrinone clearance and clinically significant side effects, but the specific creatinine clearance at which doses must be adjusted in paediatric patients is still not clear, therefore the use of milrinone is not recommended in this population (see section 4.2).
In paediatric patients milrinone should be initiated only if the patient is hemodynamically stable.
Caution should be exercised in neonates with risk factors of intraventricular haemorrhage (i.e. preterm infant, low birth weight) since milrinone may induce thrombocytopenia. In clinical studies in paediatric patients, risk of thrombocytopenia increased significantly with duration of infusion. Clinical data suggest that milrinone-related thrombocytopenia is more common in children than in adults (see sections 4.8).
In clinical studies milrinone appeared to slow the closure of the ductus arteriosus in paediatric population. Therefore, if the use of milrinone is desirable in preterm or term infants at risk of/with patent ductus arteriosus, the therapeutic need must be weighed against potential risks (see sections 4.2, 4.8, 5.2, and 5.3).
Furosemide or bumetanide should not be administered in intravenous lines containing milrinone lactate in order to avoid precipitation.
Milrinone should not be diluted in sodium bicarbonate intravenous infusion.
Whilst there is a theoretical potential interaction with calcium channel blockers, there has been no evidence of a clinically significant interaction to date.
Milrinone has a favourable inotropic effect in fully digitalised patients without causing signs of glycoside toxicity.
Fluid and electrolyte changes, as well as serum creatinine levels should be carefully monitored during treatment with milrinone. Improvement in cardiac output and consequently, diuresis, may require reduction in the dose of a diuretic agent. Potassium loss due to excessive diuresis may predispose digitalised patients to arrhythmias. Therefore, hypokalaemia should be corrected by potassium supplementation in advance of, or during milrinone use.
Pregnancy
Although animal studies have not revealed evidence of drug-induced fetal damage or other deleterious effects on reproductive function, the safety of milrinone in human pregnancy has not yet been established. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breast-feeding
There is insufficient information on the excretion of milrinone in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue milrinone therapy taking into account the benefit of breast feeding for a child and the benefit of therapy for the woman.
No studies on the effect on the ability to drive and use machines have been performed.
Adverse reactions have been ranked under heading of system-organ class and frequency using the following convention: very common (≥ 1/10); common (≥ 1/100, ≤ 1/10); uncommon (≥ 1/1,000, ≤1/100); rare (≥ 1/10,000, ≤ 1/1,000); very rare (≤ 1/10,000); not known (cannot be estimated from the available data).
Blood and lymphatic system disorders:
Uncommon: thrombocytopenia*
Not known: reduction of red blood count and/or haemoglobin concentration
*In infants and children, risk of thrombocytopenia increased significantly with duration of infusion. Clinical data suggest that milrinone-related thrombocytopenia is more common in children than in adults (see section 4.4).
Immune system disorders:
Very rare: anaphylactic shock
Metabolism and nutrition disorders:
Uncommon: hypokalaemia
Nervous system disorders:
Common: headaches, usually mild to moderate in severity
Uncommon: tremor
Cardiac disorders:
Common:
• Ventricular ectopic activity
• Non sustained or sustained ventricular tachycardia (see section 4.4)
• Supraventricular arrhythmias
• Hypotension
Uncommon:
• Ventricular fibrillation
• Angina/chest pain
Very rare:
• Torsades de pointes
The incidence of arrhythmias has not been related to dose or plasma levels of milrinone. These arrhythmias are rarely life threatening. If present, they are often associated with certain underlying factors such as pre-existing arrhythmias, metabolic abnormalities (e.g. hypokalaemia), abnormal digoxin levels and catheter insertion. Clinical data suggest that milrinone-related arrhythmias are less common in children than in adults.
Respiratory, thoracic and mediastinal disorders:
Very rare: bronchospasm
Hepatobiliary disorders:
Uncommon: liver function tests abnormal
Skin and subcutaneous tissue disorders:
Very rare: skin reactions such as rash
Renal and urinary disorders
Not known: renal failure, secondary to a concomitant hypotension.
General disorders and administration site conditions:
Not known: infusion site reaction
Paediatric population
Nervous system disorders:
Not known: interventricular haemorrhage (see section 4.4)
Congenital, familial, and genetic disorders:
Not known: patent ductus arteriosus*** (see section 4.2, 4.4, 5.2, and 5.3)
***The critical consequences of the patent ductus arteriosus are related to a combination of pulmonary overcirculation with consecutive pulmonary oedema and haemorrhage and of reduced organ perfusion with consecutive interventricular haemorrhage and necrotizing enterocolitis with possible fatal outcome as described in literature.
Long-term safety data for paediatric population are not yet available.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdose of intravenous Primacor may produce hypotension (because of its vasodilatory effect) and cardiac arrhythmia. If this occurs, Primacor Injection administration should be reduced or temporarily discontinued until the patient's condition stabilises. No specific antidote is known, but general measures for circulatory support should be taken.
Ask anything about Primacor 1mg/ml Solution for Injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.